Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib as Maintenance Therapy in Stage III EGFR-mutated NSCLC (LAURA)
NCT03521154Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2018
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jul 2018; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03521154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03521154.